MiMedx Group, a developer of regenerative biomaterials and bioimplants, has obtained US patent for its tissue grafts derived from the placenta.
The patent No.8,323,701 covers the AmnioFix brand allografts, which are produced by processing amniotic membrane tissue using the company’s proprietary PURION Process.
The allografts can be stored at room temperature for five years without the need for refrigeration, claims the company.
MiMedx Group chairman and CEO Parker Petit said the company expects some other related patents to issue in the very near future.
"Also, MiMedx has filed 25 additional patent applications relating to the use of our placental tissue allografts," Petit added.
MiMedx Group president and COO Bill Taylor said, "This is the first of many patents to come that capture the special characteristics of our PURION process for amniotic tissues, which very gently cleans the tissue, yet preserves the critical elements that are instrumental in wound healing."